Risk factors of breakthrough aspergillosis in lung transplant recipients receiving itraconazole prophylaxis
- 11 October 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Infection and Chemotherapy
- Vol. 28 (1), 54-60
- https://doi.org/10.1016/j.jiac.2021.09.020
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Correlation between Triazole Treatment History and Susceptibility in Clinically Isolated Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2012
- The impact of invasive fungal diseases on survival after lung transplantationClinical Transplantation, 2010
- Antifungal Therapeutic Drug Monitoring: Established and Emerging IndicationsAntimicrobial Agents and Chemotherapy, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Fungal infections after lung transplantationTransplantation Reviews, 2008
- Risk Factors for Invasive Aspergillosis in Solid-Organ Transplant Recipients: A Case-Control StudyClinical Infectious Diseases, 2005
- Improved survival after living-donor lobar lung transplantationThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Optimisation of Itraconazole Therapy Using Target Drug ConcentrationsClinical Pharmacokinetics, 1998
- Virologic and Pathogenetic Aspects of Cytomegalovirus InfectionClinical Infectious Diseases, 1990
- Treatment of invasive aspergillosis with itraconazoleThe American Journal of Medicine, 1989